应用甲强龙治疗中枢神经系统脱髓鞘疾病的 临床效果探讨

The Clinical Effect of Methylprednisolone in the Treatment of Central Nervous System Demyelinating Diseases

目的研究甲强龙治疗中枢神经系统脱髓鞘疾病的临床疗效。方法将2017年1月—2019年9月在该院中存在资料登记的68例中枢神经系统脱髓鞘疾病患者的个体资料,按照公式法进行两组均分,每组34例,分别记名为对照组与实验组。对实验组患者给予甲强龙进行治疗,对照组患者给予地塞米松进行治疗。根据两组患者的临床疗效和不良反应指标进行比较。结果实验组患者的治疗总有效率数据为97.06%,相较对照组的79.41%明显更高,数据对比差异有统计学意义(χ^(2)=5.100,P=0.024)。实验组患者的不良反应发生率为2(5.88%),低于对照组患者的11(32.35%),组间差异有统计学意义(χ^(2)=7.704,P=0.006)。结论在进行中枢系统脱髓鞘疾病患者的治疗时,选择甲强龙作为治疗方案,能够有助于提高治疗效果,不良反应较小,在临床上可用性较高,对于临床上的病症有较好的适应度。

Objective To study the clinical efficacy of methylprednisolone in the treatment of central nervous system demyelinating diseases.Methods The individual data of 68 patients with demyelinating diseases of the central nervous system who were registered in the hospital from January 2017 to September 2019 were divided into two groups according to the formula method.34 cases in each group,respectively named control group and experimental group.Patients in the experimental group were treated with methylprednisolone,and patients in the control group were treated with dexamethasone.According to the clinical efficacy of the two groups of patients,the temperature recovery time,adverse reactions were compared.Results The total effective rate of treatment for patients in the experimental group is 97.06%,which is significantly higher than 79.41%in the control group.The difference in data comparison was statistically significant(χ^(2)=5.100,P=0.024).The incidence of adverse reactions in the experimental group was 2(5.88%),which was lower than 11(32.35%)in the control group.The difference between the groups was statistically significant(χ^(2)=7.704,P=0.006).Conclusion In the demyelination of the central system,the therapist of the disease patient chooses methylprednisolone as the treatment plan,which can help improve the treatment effect and adverse reactions were small.It has high clinical availability and is useful for clinical treatment.The disease has good adaptability and can be promoted with higher value.